Trial Profile
A Retrospective study to identify the predictors of clinical benefit from Bevacizumab in patients with progressive glioblastoma multiforme
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 09 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology